此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of V132 in Healthy Older Participants (V132-001)

2026年10月17日 更新者:Merck Sharp & Dohme LLC

A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants

The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.

研究概览

研究类型

介入性

注册 (估计的)

280

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • California
      • Anaheim、California、美国、92801
        • 招聘中
        • Anaheim Clinical Trials ( Site 0006)
        • 接触:
          • Study Coordinator
          • 电话号码:714-774-7777
    • Florida
      • Hallandale、Florida、美国、33009
        • 招聘中
        • Velocity Clinical Research, Hallandale Beach ( Site 0003)
        • 接触:
          • Study Coordinator
          • 电话号码:954-455-5757
      • Hollywood、Florida、美国、33024
        • 招聘中
        • Research Centers of America ( Hollywood ) ( Site 0009)
        • 接触:
          • Study Coordinator
          • 电话号码:954-990-7649
      • South Miami、Florida、美国、33143
        • 招聘中
        • QPS-MRA, LLC-Early Phase ( Site 0001)
        • 接触:
          • Study Coordinator
          • 电话号码:305-722-0970
    • Missouri
      • Springfield、Missouri、美国、65802
        • 招聘中
        • Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
        • 接触:
          • Study Coordinator
          • 电话号码:417-831-2048
    • Nebraska
      • Lincoln、Nebraska、美国、68510
        • 招聘中
        • Velocity Clinical Research Lincoln ( Site 0007)
        • 接触:
          • Study Coordinator
          • 电话号码:531-530-2800
      • Omaha、Nebraska、美国、68134
        • 招聘中
        • Velocity Clinical Research, Omaha ( Site 0008)
        • 接触:
          • Study Coordinator
          • 电话号码:402-933-6500
    • Ohio
      • Columbus、Ohio、美国、43215
        • 招聘中
        • Remington-Davis, Inc. ( Site 0005)
        • 接触:
          • Study Coordinator
          • 电话号码:614-487-2560
    • Rhode Island
      • East Greenwich、Rhode Island、美国、02818
        • 招聘中
        • Velocity Clinical Research, Providence ( Site 0010)
        • 接触:
          • Study Coordinator
          • 电话号码:401-739-9350
    • Texas
      • League City、Texas、美国、77573
        • 招聘中
        • University of Texas Medical Branch ( Site 0004)
        • 接触:
          • Study Coordinator
          • 电话号码:832-340-2313

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 75年 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

  • Is in good health
  • Has body mass index (BMI) within 18.0 to 35.0 kg/m^2 (inclusive)

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
  • Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Dose Escalation

Participants will receive single intramuscular (IM) doses of a V132 formulation or comparator regimen at varying dose levels.

Experimental

Experimental

Experimental

Active Comparator

Active Comparator

实验性的:Part 2: Dose Expansion

Participants will receive single IM doses of a V132 formulation or comparator regimen. Doses will be determined based on review of Part 1 data and will not exceed maximum dose level assessed in Part 1.

Experimental

Experimental

Experimental

Active Comparator

Active Comparator

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Percentage of Participants with Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
大体时间:Up to approximately 30 minutes post vaccination

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with immediate reactions occurring within 30 minutes after any vaccination will be reported.

Up to approximately 30 minutes post vaccination
Percentage of Participants with a Solicited Injection-site Adverse Event
大体时间:Up to approximately 7 days post vaccination

An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed are redness/erythema, swelling, and tenderness/pain. The percentage of participants with a solicited injection-site adverse event will be reported.

Up to approximately 7 days post vaccination
Percentage of Participants with a Solicited Systemic Adverse Event
大体时间:Up to approximately 7 days post vaccination

An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The solicited systemic AEs assessed are muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with a solicited systemic adverse event will be reported.

Up to approximately 7 days post vaccination
Percentage of Participants With at Least 1 Unsolicited Adverse Event
大体时间:Up to approximately 28 days post vaccination

An unsolicited AE is an AE that was not solicited using a vaccination report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs. The percentage of participants with at least 1 unsolicited adverse event will be reported.

Up to approximately 28 days post vaccination
Percentage of Participants with a Serious Adverse Event
大体时间:Up to approximately 12 months post vaccination

A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event. The percentage of participants that experienced 1 or more SAEs will be reported.

Up to approximately 12 months post vaccination
Percentage of Participants With at Least 1 Medically Attended Adverse Event
大体时间:Up to approximately 12 months post vaccination

A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason. The percentage of participants with at least 1 MAAE will be reported.

Up to approximately 12 months post vaccination
Percentage of Participants Who Experienced an Adverse Event of Clinical Interest
大体时间:Up to approximately 12 months post vaccination

Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs). The percentage of participants who experienced an adverse event of clinical interest will be reported.

Up to approximately 12 months post vaccination

次要结果测量

结果测量
措施说明
大体时间
Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA)
大体时间:Up to approximately 28 days post vaccination

Opsonophagocytic activity (OPA) for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). Geometric Mean Titer (GMT) of serotype-specific OPA will be reported.

Up to approximately 28 days post vaccination
Geometric Mean Fold Rise from Baseline of Serotype-specific OPA
大体时间:Baseline (pre-vaccination) and 28 days post vaccination

The Geometric Mean Fold Rise (GMFR) from baseline in serotype-specific OPA GMTs for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). GMFR is defined as the geometric mean of the ratio of concentration at Day 28 post vaccination divided by concentration at baseline.

Baseline (pre-vaccination) and 28 days post vaccination

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Medical Director、Merck Sharp & Dohme LLC

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月12日

初级完成 (估计的)

2028年5月5日

研究完成 (估计的)

2028年5月5日

研究注册日期

首次提交

2026年7月14日

首先提交符合 QC 标准的

2026年7月14日

首次发布 (实际的)

2026年7月17日

研究记录更新

最后更新发布 (实际的)

2026年10月20日

上次提交的符合 QC 标准的更新

2026年10月17日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

其他研究编号

  • V132-001
  • V132-001 (其他标识符:MSD)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅